# Renal involvement and outcomes in patients with COVID during third wave in India

Anitha A; Anupama Y J; Arvind C; Ganesh Srinivasa Prasad; Garima Aggarwal; Girish N S; Kishan A; Krishna Penmatsa; Manisha Dassi; Manjunath Doshetty; Manjunath Kulkarni; Raveendra Madraki; Sandeep Gopinath Huilgol; Sanjay Srinivasa; Suma Raju; Yeswanth Gangaiah; Megha Kuchchal

Poster number – POS-028 ingl abstract number FRDEL-0175

### Background

COVID pandemic was associated with renal involvement and mortality. Vaccination claimed reduction in severity of disease and death rate. India had vaccinated 43.7% with 2 doses by 31.12.2021. 3rd wave was expected to

have less severe disease.

### Inclusion / Exclusion criteria

All consecutive COVID positive patients seen by a panel of Nephrologist during 3rd wave of COVID pandemic (in India) were included

Patients aged < 18 years were excluded

### Materials and Methods

Data was collected from 23 centers spread across India by an online questionnaire. This was extracted to an excel sheet and analyzed

### **Study Population**

Country - India Time - during 3rd wave of pandemic Number - 159 Age - 59.54 ± 14.98 years

Gender – Males 67.92%

Diabetes Mellitus - 93 (58.49%) Hypertension - 142 (89.31%) Ischemic Heart Disease - 30 (18.87%) COPD - 8 (5.03%)

Co-morbidities

# Baseline characteristics

On immunosuppressive medications? Yes - 27 (16.98%) Steroid\* 26 (16.35%) 17 (10.69%) Tac\* MMF\* 17 (10.69%)

Monoclonal Ab\* 2 (1.26%)

Post Tx were on >1 Imsp agents

# **Previous COVID infection**

Yes – 20 / 159 (12.58%) No – 135 / 159 (84.91%) Don't know – 4 / 159 (2.52%)


Vaccinated against COVID - 138 / 159 (86,79%) [ChAdOx1 nCoV- 19 Vaccine (Covishield) - 126 / 138 (91.3%); Whole-virion inactivated Vaccine (Covaxin) - 12 / 138 (8.7%)]

### Doses of Vaccine

Course, management and complications


1 dose – 11 / 138 (7.97%); 2 doses – 121/138 (87.68%);

Booster dose – 6 / 138 (4.35%)



Non -renal complications

ICU 30 (18.87%) HDU 7 (4.40%)



### Highest Oxygen requirement

No Supplemental Oxygen Nasal O2 - 110 (69.18%) - 26 (16.35%)

Ventimask O2 - 4 (2.52%) - 9 (5.66%) BIPAP

Ventilated - 9 (5.66%) Among 94 admitted - 45 (47.87%) did not need O2 supplementation

Among 37 admitted to ICU / HDU 9 (24.3%) needed ventilatory support

### Steroid use


Defined as need for addition of steroids or escalation of steroids for COVID: which excludes those who were on steroids for other reasons and did not need dose escalation

Steroids used in - 58 / 159 (36.48%) Steroid used for - 6.11 days

Remdesivir was used in 34.59% Antibody cocktail was used in 1.89%



# Outcomes



# Renal outcomes 0.570 ■ Vaccinated (n=138)

		No kidney disease (n=10)	Normal kidney functions with proteinuria (n=4)	AKI (n=15)	CKD (n=58)	HD patient (n=54)	Kidney Tx recipients (n=18)
	Age	54.9	44.5	67.1	63.6	60.8	42.3
	Male	4	1	14	36	39	14
	COVID vaccination	10	4	14	50	43	17
	Past COVID	4	0	0	2	12	2
	OP / IP	5/5	4 / 0	0 / 15	11 / 47	32 / 22	13 / 5
	ICU admission	0	0	9	15	5	1
	Ventilated	0	0	3	5	0	1
	HD	0	0	5	16	22	0
	Did not need dialysis	5	0	9	31	NA	5
	Death	0	0	1	3	1	1

Death (N=6)	
Age	68
Male	4
COVID vaccination	6
Past COVID	0
ICU admission	6
Ventilated	2
At admission renal status	
••••	1
CKD	3
HD patient	1
Kidney Tx recipient	1
During admission	
Needed dialysis	4

# Summary Excluded COVID Age - 59.54 Vaccinated – 86.79% COVID M – 68% Co-morbidities – DM – 58.5%; Htn – 89.3% CKD-ND +CKD-5D-Needed RRT for COVID 14.5%

 $\label{eq:Death-3.8} Death-3.8\%$  All who died had been vaccinated with 2 doses, needed ICU admission, 2 needed ventilatory support and 4 needed dialysis

### Discussion

Vaccination was preferentially given to elderly with co-morbidities, by Government mandate. Those who were not vaccinated were hence younger in age, with lesser co-morbidities.

# Conclusion

40.88% of study population did not need admission 87.68% of the study population were vaccinated with 2 doses of vaccine Based on O2 requirement, severe COVID was seen in 19 / 159 (11.95%) Vaccine did not prevent severe COVID

# Limitations

Small cohort / No follow up

Acknowledgement We acknowledge the help provided by Bloom
Value Corporation in collecting the data